Sulconazole Nitrate
(Synonyms: 硝酸硫康唑,(±)-Sulconazole mononitrate) 目录号 : GC11909An azole antifungal
Cas No.:61318-91-0
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Sulconazole nitrate is an antifungal medication of the imidazole class.
After cutaneous application of radioactive solutions of Sulconazole nitrate in the hairless rat, the total absorption of the substance by the skin, estimated from the sum of the cumulative urinary and fecal excretions over 96 h, is 2.4% of the dose administered. The elimination reaches a maximum between 6 and 24 h and is virtually complete after 96 h. The excretion is almost equally distributed between the urine and the feces, which corresponds to an intense elimination via the biliary tract. The quantities present in the stratum corneum, epidermis and dermis at the end of the period of contact constituted another estimation of the total absorption of the substance which confirmed the previous estimation (3.6% of the dose). The measurement of the concentrations of Sulconazoleand its metabolites in the various layers of the skin reveals a high affinity of the substance for the stratum corneum, where it remains present in large quantities for more than 48 h. This affinity is due to the very intense lipophilia of the molecule. The concentrations in the other tissues are inversely proportional to the distance from the surface of the skin and are virtually nil in the circulating blood[3].
References:
[1]. Zaro BA, et al. Species variation in percutaneous absorption of sulconazole nitrate, a new anti-fungal agent. Proc West Pharmacol Soc. 1982;25:357-9.
[2]. Bielejewska A, et al. Effect of (+) or (-) camphorsulfonic acid additives to the mobile phase on enantioseparations of some basic drugs on a Chiralcel OD column. J Chromatogr A. 2005 Aug 12;1083(1-2):133-40.
[3]. Hercelin B, et al. Pharmacokinetics of cutaneous Sulconazole nitrate in the hairless rat: absorption, excretion, tissue concentrations. Eur J Drug Metab Pharmacokinet. 1993 Apr-Jun;18(2):149-54.
Cas No. | 61318-91-0 | SDF | |
别名 | 硝酸硫康唑,(±)-Sulconazole mononitrate | ||
化学名 | 1-[2-[(4-chlorophenyl)methylsulfanyl]-2-(2,4-dichlorophenyl)ethyl]imidazole;nitric acid | ||
Canonical SMILES | C1=CC(=CC=C1CSC(CN2C=CN=C2)C3=C(C=C(C=C3)Cl)Cl)Cl.[N+](=O)(O)[O-] | ||
分子式 | C18H15Cl3N2S.HNO3 | 分子量 | 460.76 |
溶解度 | ≥ 16.1mg/mL in DMSO | 储存条件 | 4°C, away from moisture and light |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.1703 mL | 10.8516 mL | 21.7033 mL |
5 mM | 0.4341 mL | 2.1703 mL | 4.3407 mL |
10 mM | 0.217 mL | 1.0852 mL | 2.1703 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。